Abbott Laboratories (NYSE:ABT) Shares Bought by Bay Colony Advisory Group Inc d b a Bay Colony Advisors

Bay Colony Advisory Group Inc d b a Bay Colony Advisors increased its stake in Abbott Laboratories (NYSE:ABT) by 1.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,527 shares of the healthcare product maker’s stock after purchasing an additional 182 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors’ holdings in Abbott Laboratories were worth $2,096,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of ABT. Impax Asset Management Group plc boosted its stake in Abbott Laboratories by 0.5% in the 3rd quarter. Impax Asset Management Group plc now owns 557,608 shares of the healthcare product maker’s stock worth $63,573,000 after purchasing an additional 2,754 shares in the last quarter. United Advisor Group LLC acquired a new stake in Abbott Laboratories during the 3rd quarter valued at approximately $302,000. Avidian Wealth Enterprises LLC lifted its stake in Abbott Laboratories by 1.9% during the 3rd quarter. Avidian Wealth Enterprises LLC now owns 8,213 shares of the healthcare product maker’s stock valued at $936,000 after acquiring an additional 157 shares during the period. Beacon Financial Advisory LLC acquired a new stake in Abbott Laboratories during the 3rd quarter valued at approximately $201,000. Finally, Maia Wealth LLC lifted its stake in Abbott Laboratories by 6.2% during the 3rd quarter. Maia Wealth LLC now owns 2,621 shares of the healthcare product maker’s stock valued at $305,000 after acquiring an additional 154 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the company’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $128.50, for a total value of $3,054,573.50. Following the transaction, the executive vice president now owns 125,697 shares of the company’s stock, valued at $16,152,064.50. This represents a 15.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Eric Shroff sold 562 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $138.17, for a total transaction of $77,651.54. Following the completion of the transaction, the senior vice president now directly owns 31,970 shares in the company, valued at $4,417,294.90. The trade was a 1.73 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 25,282 shares of company stock valued at $3,263,348. 1.10% of the stock is currently owned by insiders.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $134.90 on Friday. The firm has a market cap of $233.97 billion, a PE ratio of 17.63, a PEG ratio of 2.52 and a beta of 0.75. The firm has a fifty day moving average of $124.90 and a 200 day moving average of $118.53. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. Abbott Laboratories has a one year low of $99.71 and a one year high of $141.23.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 EPS for the quarter, hitting the consensus estimate of $1.34. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The company had revenue of $10.97 billion during the quarter, compared to analyst estimates of $11.03 billion. During the same quarter in the previous year, the firm earned $1.19 EPS. The firm’s revenue was up 7.2% compared to the same quarter last year. As a group, research analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be issued a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.75%. The ex-dividend date of this dividend is Tuesday, April 15th. Abbott Laboratories’s payout ratio is 30.85%.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Evercore ISI lifted their price objective on shares of Abbott Laboratories to $136.00 and gave the company a “buy” rating in a research note on Thursday, January 2nd. Royal Bank of Canada restated an “outperform” rating and set a $135.00 price objective on shares of Abbott Laboratories in a research note on Tuesday, January 21st. Argus upgraded shares of Abbott Laboratories to a “strong-buy” rating in a research note on Tuesday, January 28th. Wells Fargo & Company lifted their price objective on shares of Abbott Laboratories from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, January 23rd. Finally, The Goldman Sachs Group lifted their target price on shares of Abbott Laboratories from $138.00 to $154.00 and gave the company a “buy” rating in a report on Tuesday. Four equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $137.19.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.